Group 1 - The core viewpoint of the articles highlights the financial performance of Shenwei Pharmaceutical (02877), reporting a net profit of RMB 950 million, which represents a year-on-year increase of 13.1% despite a decline in revenue [1] - The company's total revenue for the fiscal year ending December 31, 2025, was RMB 3.135 billion, a decrease of 17.0% compared to the previous year, with a gross margin of 72.3%, down from 75.0% last year [1] - The company declared an interim dividend of RMB 0.43 per share for 2026, with earnings per share reported at RMB 1.26 [1] Group 2 - The traditional Chinese medicine granule industry is experiencing a significant adjustment period characterized by declining sales due to multiple policy impacts, including the implementation of national standards and the normalization of provincial centralized procurement [2] - The sales revenue of the company's traditional Chinese medicine granules decreased by 14.4% during the year, reflecting the overall industry trend [2] - The company is actively working to expand its sales team, control costs, and enhance regional and product competitiveness, with expectations of regaining growth as the industry landscape stabilizes [2]
神威药业(02877)发布年度业绩 净利润9.5亿元 同比上升13.1% 集采中标八大产品夯实市场基础